




Palmitic Acid Hydroxy Stearic Acids Activate GPR40 Which is Involved in Their Beneficial Effects on Glucose Homeostasis.
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	Type 2 Diabetes (T2D) is a global epidemic (International Diabetes Federation Atlas 2013) characterized by hyperglycemia due to impaired pancreatic islet function and insulin resistance in peripheral tissues. Despite advances in understanding the molecular mechanisms contributing to T2D and the development of new treatment modalities, the medical management of T2D remains inadequate (Madsbad et al., 2011; Aroda et al., 2012; Pratley et al., 2010). At present, many available treatment strategies including analogues of the incretin, GLP-1, and DPP-lV inhibitors work primarily by increasing insulin secretion. Other effective agents promote glucose excretion (Campbell & Drucker 2013; Meier 2012). But there is still a need for effective and safe agents that enhance insulin sensitivity to improve diabetic treatment and prevent complications.
	We recently discovered a structurally novel class of endogenously synthesized lipids, branched fatty acid esters of hydroxy fatty acids (FAHFAs), with beneficial metabolic and anti-inflammatory effects (Yore et al., 2014). More than 16 FAHFA family members have been identified (Yore et al., 2014; Zhang et al., 2016; Yan et al., 2015).  Levels of one of the FAHFA family members, palmitic acid hydroxy stearic acid (PAHSAs), are markedly lower in serum and adipose tissue of insulin-resistant humans. PAHSA levels correlate strongly with insulin sensitivity as measured by euglycemic clamps in humans (Yore et al., 2014).  Acute oral treatment with 5- or 9-PAHSA isomers in chow and high-fat diet (HFD)-fed mice improves glucose tolerance and augments insulin and GLP-1 secretion in vivo. In vitro, PAHSAs directly enhance GLP-1 secretion from enteroendocrine cells and glucose-stimulated insulin secretion from human pancreatic islets (Yore et al., 2014). Furthermore, PAHSAs have anti-inflammatory effects including decreasing adipose inflammation in HFD mice and attenuating LPS-induced dendritic cell activation and cytokine production (Yore et al., 2014). Although we reported that a single dose of PAHSAs acutely improves glucose tolerance, whether PAHSAs have effects on insulin sensitivity in vivo has not been investigated. Therefore, the first aim of this study was to determine whether PAHSA treatment enhances insulin sensitivity in vivo, and the second aim was to determine whether the beneficial effects of PAHSAs are sustained with chronic treatment. 
The receptors responsible for PAHSA effects on insulin secretion and insulin action in vivo have not been identified. The effect of PAHSAs to enhance insulin-stimulated glucose transport in adipocytes is mediated by the G-protein coupled receptor, GPR120 (Yore et al., 2014), but PAHSAs are likely to activate other GPCRs because of the diversity of their actions in multiple tissues. Major pharmaceutical companies have had high-priority programs screening for activators of GPR120 and GPR40 to treat T2D. Molecules that activate more than one of these GPCRs may be more effective for T2D treatment than agonists for single receptors.
	Recent research has focused on identifying key agonists and receptors mediating nutrient-induced GLP-1 and insulin secretion. The long-chain fatty acid receptor, GPR40 is the most abundant GPCR expressed in islet β-cells and is also expressed on intestinal L-cells where it contributes to GLP-1 release along with GPR120 (Itoh et al., 2003; Edfalk et al., 2008). GPR40 activation augments glucose-stimulated insulin secretion (GSIS) and improves glycemia in rodent T2D models (Itoh et al., 2003; Steneberg et al., 2005; Latour et al., 2007), and the GPR40 agonist TAK-875 lowers fasting and postprandial blood glucose and HbA1c levels in humans (Leifke et al., 2012; Burant et al., 2012). Because PAHSAs acutely augment GSIS directly from human islets (Yore et al., 2014), the third aim of this study was to determine whether PAHSAs activate GPR40 and whether this contributes to their beneficial effects in vivo. Here we show that PAHSAs directly activate GPR40 which is important for PAHSA effects on glucose homeostasis in both chow and HFD-fed mice.







Chronic PAHSA treatment improves insulin sensitivity and glucose tolerance, and reduces adipose tissue inflammation in chow-fed mice without altering food intake or adiposity
Up to 18 weeks of treatment with 5- and 9-PAHSA by subcutaneous mini pump in chow-fed male C57bl6 mice had no effect on body weight, fat mass (Figure 1A), food intake, lean mass, serum triglycerides or free fatty acid levels (Supplementary Figure 1A and 1B).  Serum 5- and 9-PAHSA levels increased 2-fold with 2 months of treatment compared to vehicle-treated mice (Figure 1B). After 5 months of treatment, only 9-PAHSA levels were elevated in serum in the treatment group (Figure 1B). However, 5- and 9-PAHSA levels were increased 1.5- to 3-fold in perigonadal (PG) and subcutaneous (SC) white adipose tissue and brown adipose tissue. In liver 9-PAHSA levels were elevated 2.5-fold in treated mice, and 5-PAHSA was easily detectable even though this isomer was not found in liver of vehicle-treated mice as expected (Yore et al., 2014) (Figure 1B). 5- and 9-PAHSA levels were not increased in the pancreas or brain with chronic PAHSA treatment (Figure 1B). 
 5- and 9-PAHSA treatment improved insulin sensitivity as early as 13 days of treatment and these effects were sustained for at least 5 months (Figure 1C). Glucose tolerance (Figure 1D) was also improved similar to the effects reported with a single dose (Yore et al. 2014). Loss of first phase insulin response to glucose is one of the major and early impairments of islet β-cell function in T2D (Luzi and DeFronzo 1989). Restoration of this response is associated with significant improvement in postprandial glucose excursion (Bruce et al., 1988). Here we show that, chronic 5- and 9-PAHSA treatment enhances insulin secretion in response to glucose by 40% over vehicle-treated mice (Figure 1E, left panel). GLP-1 levels tend to be reduced at baseline in PAHSA-treated mice, and PAHSA treatment enhanced glucose-stimulated GLP-1 secretion 225% over vehicle (Figure 1E, right panel). Therefore, not only does an acute oral dose of PAHSAs improve first-phase insulin and GLP-1 responses to glucose (Yore et al., 2014), but this effect is maintained over 5 months without tachyphylaxis or islet β-cell exhaustion. To confirm that the beneficial effects of PAHSAs on metabolic parameters are distinct from effects of ordinary fatty acids, we performed similar studies with palmitate since PAHSAs are made up of palmitate and hydroxystearic acid. Palmitate treatment at the same dose used for PAHSAs does not have any favorable effects on glucose tolerance, insulin tolerance, or glucose-stimulated insulin or GLP-1 secretion (Figure 1F-1I). 
In addition, at the same concentration as PAHSAs (20µM), palmitate did not augment GSIS in cultured islets (Supplementary Figure 1C).  This was not because of lower palmitate uptake into cells since lipid uptake as measured by the ratio of PAHSA or palmitate in the low density microsomes, high density microsomes, and cytosol fractions compared to the plasma membranes, appeared greater for palmitate than for PAHSAs (Supplemental Figure 1D). 
We next investigated whether chronic PAHSA treatment reduces adipose tissue (AT) Inflammation. PAHSA treatment reduced the total number of AT CD11c+ (pro-inflammatory) macrophages with no effect on AT CD206+ (anti-inflammatory) macrophages (Figure 1J; Gating strategy in Supplementary Figure 1E). The total number of AT macrophages tended to be reduced with PAHSA treatment (Figure 1J) with no change in monocytes or neutrophils (Supplementary Figures 1F). Moreover, PAHSA treatment reduced the number of macrophages positive for IL-1β or TNF-α (Figure 1J). Together, these data indicate that chronic PAHSA treatment reduces AT Inflammation which could contribute to enhanced glucose-insulin homeostasis in chow-fed mice.
PAHSAs activate GPR40 and this plays a role in their effects on insulin secretion
Since free fatty acids can induce insulin and GLP-1 secretion through GPR40, we investigated the role of GPR40 in mediating PAHSA effects. 9-PAHSA potentiated GSIS in isolated human islets, and pharmacological inhibition of GPR40 using a GPR40 antagonist, GW1100, completely blocked this effect (Figure 2A). Furthermore, knocking down GPR40 in pancreatic β-cells (MIN6 cells) using a combination of three different GPR40 siRNAs completely reversed 9-PAHSA-potentiated GSIS without altering insulin secretion at low glucose (Figure 2B, GPR40 knockdown efficiency in Supplementary Figure 2A). Thus, both pharmacologic and genetic approaches indicate that PAHSAs augment GSIS by activating GPR40. 
To determine whether PAHSAs directly activate GPR40, we transfected HEK293 cells with GPR40 and SRE-luc. 9-PAHSA activates GPR40 in a dose-dependent manner (Figure 2C). 5-PAHSA also activates GPR40 (Supplementary Figure 2B). 9-PAHSA-induced GPR40 activation was attenuated by a GPR40 antagonist, in a dose-dependent manner (Figure 2D). We next determined whether PAHSAs are full or partial GPR40 agonists. 9-PAHSA increased Ca2+ flux similar to the positive control Linoleic acid, and the GPR40 antagonist, GW1100 attenuated this effect (Figure 2E). 9-PAHSA had no effect on intracellular cAMP levels (Figure 2F). Thus, PAHSAs are partial, not full, agonists for GPR40. We also tested whether GPR40 mediates the effects of PAHSAs on GLP-1 secretion directly in STC-1 enteroendocrine cells. Both 5- and 9-PAHSAs augmented GLP-1 secretion in STC-1 cells by 1.5- to 2-fold, but GPR40 antagonism did not reduce this (Supplementary Figure 2C). This suggests that the direct effects of PAHSAs to augment GLP-1 secretion in enteroendocrine cells are independent of GPR40. 
Inhibition of GPR40 reverses the beneficial effects of 5- and 9-PAHSA on both glucose tolerance and insulin sensitivity
To determine whether the GSIS effects of PAHSAs are mediated by GPR40 in vivo, vehicle- and 5- and 9-PAHSA-treated chow-fed mice were injected with the GPR40 antagonist, DC260126. A single dose of DC260126 attenuated  the beneficial effects of PAHSAs on insulin sensitivity and glucose tolerance (Figure 2G-2H, compare to Figure 1C-1D), but had no effect in the vehicle-treated mice(Supplementary Figure 2D-2F). There was no effect of GPR40 inhibition on glycemia at baseline or 5 minutes post glucose administration (Figure 2I and Supplementary Figure 2G). However, GPR40 inhibition lowered baseline insulinemia (30 min after DC260126) and completely blocked glucose-stimulated insulin secretion (GSIS) in PAHSA-treated mice (Figure 2I), but had no effect in vehicle-treated mice (Supplementary Figure 2G). In PAHSA- and vehicle-treated mice, GPR40 inhibition did not affect glucose-stimulated GLP-1 secretion (Figure 2I and Supplementary Figure 2G). Thus, PAHSAs stimulate insulin secretion through GPR40 and these effects are independent of GLP-1 secretion.
We also determined whether the effects of chronic PAHSA treatment in vivo are sustained when pancreatic islets are removed and studied ex vivo. Compared to islets isolated from vehicle-treated mice, in islets from PAHSA-treated mice ex vivo there was no further augmentation of GSIS (Supplementary Figure 2H). This suggests the continuous presence of PAHSAs is required to trigger the GPR40 activity. 
Blockade of the GLP-1 receptor reverses the beneficial effects of chronic PAHSA treatment on glucose tolerance but not insulin sensitivity 
To determine whether PAHSA-induced improvements in glucose tolerance and insulin sensitivity are mediated through enhanced GLP-1 secretion, we injected vehicle- and 5- and 9-PAHSA-treated mice with the GLP-1 receptor antagonist, Exendin (9-39) (Figure 3A). A single dose of Exendin (9-39) completely reversed PAHSA-induced improvement in glucose tolerance in chow-fed mice (Figure 3B; Supplementary Figure 3A) but not insulin sensitivity (Figure 3C). In PAHSA-treated mice, GLP-1 receptor blockade increased glycemia at baseline (30 minutes after Exendin treatment) (Figures 3B-3D) and at 5 minutes post glucose administration (Figure 3D). In addition, Exendin (9-39) treatment attenuated PAHSA-mediated increase in GSIS. Exendin (9-39) increased baseline but attenuated glucose-stimulated GLP-1 secretion (Figure 3D). In vehicle-treated mice, Exendin (9-39) had no effect on baseline glucose (30 minutes after Exendin treatment) or on glucose tolerance except at 45 min after glucose administration (Supplemental Figure 3B). There was also no effect on insulin sensitivity or on glycemia at baseline or at 5 minutes post glucose administration (Supplementary Figure 3C-3D). Furthermore, GLP-1R antagonism in vehicle-treated mice increased glucose-stimulated insulin and GLP-1 secretion (Supplementary Figure 3D). This increase in GLP-1 secretion may be a response to GLP-1 receptor blockade and mostly likely stimulates insulin secretion. As expected, PAHSAs do not directly activate GLP-1R (Supplementary Figure 3E) which is activated by peptides (GLP-1) not lipids. Thus these experiments indicate that GLP-1 action is necessary for the full effects of PAHSAs on glucose tolerance but not insulin sensitivity, and this results from PAHSA-mediated increase in GLP-1 secretion. These observations are in accordance with a study in T2D people, in which GLP-1 improves glycemic control by increasing insulin secretion and inhibiting glucagon secretion, without improving insulin sensitivity (Vella et al., 2000).
Chronic PAHSA treatment improves insulin sensitivity and glucose tolerance, and reduces adipose tissue inflammation in HFD-fed mice without altering food intake or adiposity.
15-18 weeks of 9-PAHSA treatment via subcutaneous mini pumps in HFD-fed male C57bl6 mice did not alter body weight, fat mass, lean mass, food intake, or serum triglycerides or free fatty acid levels (Figure 4A, Supplementary Figure 4A-4B). 9-PAHSA levels are elevated ~2 fold in serum and liver (Figure 4B) and ~33-42% in PG and SQ WAT compared to vehicle-treated HFD mice. 9-PAHSA levels are restored to chow-fed mouse levels in serum and PG WAT but not completely restored in SQ WAT (Figure 4B and Figure 1B). Chronic PAHSA treatment in HFD-fed mice improved insulin sensitivity (Figure 4C and Supplementary Figure 4C) and glucose tolerance (Figure 4D) compared to vehicle-treated HFD-fed mice and these effects were sustained for at least 4 months. We found that 9-PAHSA treatment (12 mg/kg per day) was more effective than a split dose of 5- and 9-PAHSA (6 mg/kg of each) in HFD mice (data not shown) although the combination treatment consistently lowered glycemia 5 hours after food removal (Supplementary Figure 4D). Further studies showed 9-PAHSA lowered glycemia at 5 minutes post-glucose in HFD mice compared to vehicle-treated HFD mice with similar insulin levels (Figure 4E), supporting enhanced insulin sensitivity. Also in support of this, chronic 9-PAHSA treatment in HFD-fed mice prevented the increase in islet mass seen in vehicle-treated HFD-fed mice (Figure 4F). This again suggests that the same insulin levels are more efficient in lowering glucose in PAHSA-treated HFD mice and expansion of islet mass is not necessary. In contrast to PAHSA treatment in chow-fed mice (Figure 1E), chronic PAHSA treatment in HFD-fed mice did not enhance glucose-stimulated insulin or GLP-1 secretion compared to vehicle-treated HFD mice (Figure 4E) but similar insulin levels lowered glucose more in PAHSA-treated HFD mice. Thus, PAHSA beneficial effects on glucose homeostasis in HFD-fed mice are independent of changes in glucose-stimulated insulin or GLP-1 secretion and appear to involve increased insulin sensitivity. AT TNF-α mRNA levels are lower in PAHSA-treated HFD-fed mice compared to vehicle-treated HFD-fed mice (Figure 4G), indicating that reduced AT Inflammation could contribute to the enhanced glucose-insulin homeostasis in HFD-fed mice. Overall, the PAHSA-mediated beneficial effects in HFD-fed mice are more moderate than effects in chow-fed mice. This may be in part due to lack of full restoration of PAHSA levels in SC AT.
Since PAHSA beneficial effects on glucose homeostasis in chow-fed mice are in part mediated by GPR40 (Figure 2G and 2H), we studied the role of GPR40 in the PAHSA effects in HFD-fed mice. The GPR40 antagonist, DC260126, reverses the beneficial effects of PAHSAs on insulin tolerance test and glucose tolerance test in HFD-fed mice (Figure 4H and 4I), and had no effect in the vehicle-treated HFD mice (Supplementary Figure 4E and 4F). This effect of GPR40 inhibition in PAHSA-treated HFD mice is mainly due to the reversal of the effects of PAHSAs to lower glycemia at time “0” min of the OGTT and ITT (Figure 4H and 4I, Supplementary Figure 4G and 4H). These data suggest that GPR40 mediates at least some of the beneficial effects of PAHSAs in HFD-fed mice similar to the effects in chow-fed mice.
Prior to this study, we investigated only the acute PAHSA effects on glucose homeostasis, primarily with a single dose (Yore et al., 2014). Furthermore, we did not report data on insulin sensitivity. A major advance of this study is demonstrating that PAHSAs enhance insulin sensitivity. This is important since a major “unmet medical need” is safe insulin-sensitizing agents. None of the anti-diabetic drugs on the market are primarily insulin-sensitizers except the thiazolidinediones which have adverse effects that have markedly curtailed their use. Safe insulin-sensitizing agents could be used both to prevent and treat insulin resistance, T2D, and cardiovascular complications. 
Since PAHSAs correlate highly with insulin sensitivity in humans, and are reduced in serum and SC AT of insulin-resistant people and HFD-fed mice, we designed the current study to restore circulating and tissue PAHSA levels within the physiologic range (Yore et al., 2014). Although we achieved this in chow-fed mice and in serum and PG WAT of HFD-fed mice, we did not fully restore levels in SC AT of HFD-fed mice. This could contribute to the more modest effects on insulin sensitivity and glucose tolerance in HFD mice. The effects in chow-fed mice are also greater with a mixed background, which is more relevant to human disease, than inbred C57bl6 mice.  Future studies will investigate the effects of PAHSA treatment in HFD mice on a mixed genetic background. 
Another major advance is that we identified a new receptor that is directly activated by PAHSAs, GPR40. GPR40 blockade in chow-fed mice attenuates PAHSA-mediated improvements in glucose tolerance, insulin sensitivity, and insulin secretion but not glucose-stimulated GLP-1 secretion. The fact that PAHSAs have direct effects on insulin secretion independent of GLP-1 is supported by our data showing they stimulate GSIS in isolated human islets (Figure 2A; Yore et al., 2014).  In HFD-fed mice, GPR40 blockade attenuates PAHSA-mediated beneficial effects on glucose tolerance and systemic insulin sensitivity even though chronic PAHSA treatment does not potentiate GSIS. The GLP1 receptor plays a role in some but not all PAHSA effects in chow-fed mice since GLP-1R blockade attenuates PAHSA-mediated improvement only in glucose tolerance and not in insulin sensitivity. These observations do not eliminate a role for GPR120 which could mediate the PAHSA effects on GLP1 secretion as well as glucose uptake (Yore et al 2014) and which has some overlapping biologic effects with GPR40. 









Animal studies and measurement of metabolic parameters
Chow-fed (Purina Lab diet, 5008) male C57Bl/6J wild-type mice (Jackson Laboratories) and in-house bred mixed background mice (C57Bl/6J and FVB) were randomized to treatment group based on body weight at 8 weeks of age and implanted with subcutaneous mini pumps (Alzet, Model 2006). Similarly, randomized male C57Bl/6J wild-type mice were placed on HFD (Research Diets, Td93075) at 6 weeks of age. After 8 weeks on HFD, insulin resistance was confirmed by an insulin tolerance test. Mini pumps were implanted after 9 weeks on HFD. All mice were singly housed in ventilated cages with ad libitum access to food and water. All animals were kept on a 14 hr light, 10 hr dark schedule at an ambient temperature between 72-74˚F. Body weight and food intake were measured weekly and body composition was measured by MRI. Insulin tolerance test and oral glucose tolerance test were performed as previously described (Moraes-Vieira et al. 2014) following 5-hour food removal. All animal care and use procedures were in strict accordance with, and approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center, Boston, MA.
Experimental treatments, materials and chemical reagents
Mini pumps filled with either vehicle (50% PEG-400, 0.5% Tween-80, 49.5% distilled water) or 5- and 9-PAHSAs (Chow: 2mg/kg of each PAHSA or 2mg/kg of palmitate; HFD: 6mg/kg of each PAHSA or 12mg/kg of 9-PAHSA) were inserted subcutaneously at 8-weeks of age in chow-fed and 15 weeks of age in HFD-fed mice. Minipumps were changed every 42 days. Insulin and D-glucose (Sigma Aldrich, St. Louis, MO) were used for tolerance tests. For in vivo studies, the GLP-1R antagonist, Ex(9-39) (5µg/mouse) and the GPR40 antagonist, DC260126 (5mg/kg; Tocris Bioscience) was administered intraperitoneally. The GPR40 antagonist, GW1100 (10µM, Cayman Chemicals) was used for in vitro studies. All chemical reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. ELISA kits were obtained from Crystal Chem (Mouse Insulin), Millipore (Mouse GLP-1) and Alpco Diagnostics (Human Insulin). Organic solvents for LC-MS were purchased from Honeywell Burdick & Jackson.
PAHSA extraction and measurements from serum and tissues
Lipid extraction and PAHSA measurements were performed as described (Zhang et al., 2016). 
Anti-inflammatory effects of 5- and 9-PAHSAs in vivo
Perigonadal AT stromal vascular fraction cells were harvested and surface markers were stained with monoclonal antibodies (Biolegend) for multicolor flow cytometry. For intracellular cytokine measurements, cells were stained as previously described (Moraes-Vieira et al., 2014).    
GPR40 Reporter assay
HEK293 cells transfected with GPR40 and SRE-luc 44-235 were treated with DMSO control, 5-PAHSA (100µM), or 9-PAHSA (0-100µM). Transfected cells were treated with GW1100 (0-10µM) in combination with DMSO or 9-PAHSA.    
Glucose-stimulated insulin secretion (GSIS) in human islets
Human islets from normal donor were obtained from BADERC Core facility, MGH, Bosotn. GSIS was assessed as previously outlined (Kowluru et al., 2010).  Briefly, human islets were cultured overnight in human islet media and stimulated with either 2.5mM or 20mM glucose in presence or absence of DMSO, 9-PAHSA (20µM), and GW1100 (10µM) for 45 mins.  At the end, media was collected and insulin was quantitated by ELISA (Alpco Diagnostics).

Cell uptake study
INS-1 cells were treated with 20µM double labelled PAHSA and 13C-palmitate for 1 hour. At the end of incubation, cells were collected in homogenization buffer with protease inhibitor and homogenized. Plasma membrane, high density microsome, low density microsome and cytosolic fractions were obtained as described by Evans et al., 2009. Protein was quantified using BCA reagent and purity of subcellular fractions was determined by Western blot. Double labelled PAHSA and 13C-Palmitate in different fractions were measured as previously described (Zhang et al., 2016).
Determination of β-cell mass
Pancreata from mice treated chronically with vehicle or 9-PAHSA by minipumps were collected and fixed in 10% formalin. From each pancreas, 2-3 duplicate sections were imaged to determine islet β-cell mass as previously described (Iglesias et. al., 2012). 
Data Analysis
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Figure 1: Chronic PAHSA treatment improves insulin sensitivity and glucose tolerance, and reduces adipose tissue inflammation without altering food intake or adiposity.
(A) Body weight and fat mass of C57bl6 male chow-fed mice treated with 5- and 9-PAHSAs (2mg/kg body weight per day of each) via mini pumps. n=16/group. (B) 5- and 9-PAHSA levels in sera at 2 and 5 months, and tissues at 5 months of 5-and 9-PAHSA treatment. n=5-6/group. (C) insulin tolerance tests (ITT) and (D) oral glucose tolerance tests (OGTT) 5-hours after food removal in vehicle- and PAHSA-treated mice. n=8-11/group. For A-D, *p<0.05 vs. vehicle. (E) Serum insulin and GLP-1 levels 5 min postglucose challenge in vehicle- and PAHSA-treated mice. n=14-16/group. *p<0.05 vs. baseline within same treatment, #p<0.05 vs. vehicle at same time point, $p=0.08 vs. vehicle at same time point. (F) ITT and (G) OGTT 5-hours after food removal in vehicle-, Palmitate- and PAHSA-treated outbred mice. n=7-9/group. (H-I) Serum insulin and GLP-1 levels 5 min postglucose challenge in vehicle-, Palmitate and PAHSA-treated outbred mice. n=7-9/group. *p<0.05 vs. baseline within same treatment, #p<0.05 vs. vehicle at same time point. (J) Number of adipose tissue (AT) CD11c+, CD206+, total number of AT macrophages (ATM), and macrophages expressing IL-1β and TNFα from PG WAT were measured by flow cytometry. n=4-5/group. *p<0.05 vs. vehicle; †p<0.08 vs. vehicle. Data are means±SEM. 
Figure 2: PAHSAs directly activate GPR40, and GPR40 antagonism reverses PAHSA-mediated improvements in glucose tolerance and insulin sensitivity and insulin secretion.
(A) Human islets were treated with DMSO, 9-PAHSA (20µM), GW1100 (10µM), or 9-PAHSA+GW1100 for 45 minutes during glucose stimulation (Low glucose=2.5 mM; High glucose=20 mM). 75 islets/condition. *p<0.05 vs. respective 2.5mM glucose, #p<0.05 vs. DMSO 20mM glucose, †p<0.05 vs. 9-PAHSA 20mM glucose.  (B) MIN6 cells, were transfected with scrambled or GPR40 siRNA, and treated with either DMSO or 9-PAHSA (20µM) for 45 minutes during glucose stimulation (Low glucose=2.5 mM; High glucose=20 mM). n=10 wells/condition. *p<0.05 vs. respective 2.5mM glucose, #p<0.05 vs. DMSO 20mM glucose scrambled siRNA, $ p<0.05 vs. 9-PAHSA 20mM glucose scrambled siRNA. (C) Reporter assay in HEK293 cells transfected with mouse GPR40 and SRE-luc 444-235, and treated with 9-PAHSA. n=3. (D) GPR40 reporter assay in HEK293 cells treated with either DMSO or 9-PAHSA with GW1100. n=3/condition. (E) Calcium flux assay in mGPR40-stably transfected cells in presence of DMSO, Linoleic acid, 9-PAHSA and GW1100. n=3/condition (F) cAMP assay in mGPR40-stably transfected cells in presence of DMSO, cAMP agonist control, and 9-PAHSA. n=3/condition. 5-hours after food removal PAHSA-treated mice were injected with either DMSO or DC260126 intraperitoneally followed by a glucose gavage or insulin I.P. injection after 30 minutes for an OGTT (G) or ITT (H). (I) Following the protocol in Fig-1E, glycemia, insulin and GLP-1 levels were measured in PAHSA-treated mice before and 5 min post glucose gavage. n=8-10/group. *p<0.05 vs. baseline within same treatment, #p<0.05 vs. Vehicle DMSO at same time point. Data are means±SEM.
Figure 3: The GLP-1R antagonist, Exendin (9-39), reverses the effect of 5- and 9-PAHSAs on improved glucose tolerance.
(A) 5-hours after food removal, PAHSA-treated mice were injected with either PBS or 5µg Ex(9-39) i.p. followed 30 minutes later by OGTT (B) or  ITT (C). n=14-16/group. *p<0.05 vs. PAHSA PBS. (D) Glycemia, insulin and GLP-1 levels were measured in PAHSA-treated mice before and 5 min post glucose gavage. n=8-10/group. *p<0.05 vs. baseline within same treatment, #p<0.05 vs. Vehicle PBS at same time point. Data are means±SEM. 
Figure 4: Chronic PAHSA treatment improves insulin sensitivity and glucose tolerance, and reduces adipose tissue inflammation in high fat diet-fed mice without altering food intake or adiposity.
(A) Body weight and fat mass in C57bl6 male chow- and HFD-fed mice treated with 9-PAHSA via mini pumps. n=16/group. (B) 9-PAHSA levels in sera and tissues after 4 months of 9-PAHSA treatment. n=5-6/group. (C-D) ITT (on day 98 of the treatment) and OGTT (on day 57 of the treatment) 5-hours after food removal in vehicle and PAHSA-treated mice. Area under the curve for OGTT. n=8-14/group. For A-D, *p<0.05 vs. HFD vehicle; # p<0.05 vs HFD vehicle; $ p<0.05 vs. Chow vehicle. (E) Serum glucose, insulin, and GLP-1 levels 5 min postglucose challenge in vehicle and PAHSA-treated mice after 70 days of treatment. n=7-8/group. *p<0.05 vs. vehicle at same time point. (F) β-cell mass quantification (n=2-3 sections per mouse and 5-6 mice per group). *p< 0.05 vs. HFD-vehicle. (G) TNFα mRNA levels in PG WAT in HFD Vehicle- and PAHSA-treated mice. n=8-9/group. *p<0.05 vs. vehicle. 5-hours after food removal, PAHSA-treated mice were injected with either DMSO or DC260126 i.p. followed 30 minutes later by ITT (H) or OGTT (I).  n=5-6/group. *p<0.05 vs. HFD PAHSA DMSO. Data are means±SEM.
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